Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study
Cladribine treatment in highly active RRMS patients protects the brain from atrophy, with stabilization occurring over 2 years after initiation. The extended observation period highlights its sustained benefits compared with shorter clinical trials.
Authors
- Chen Hoffmann (ORCID: https://orcid.org/0000-0002-5339-9495)
- Yehuda Warszawer (ORCID: https://orcid.org/0000-0001-7919-807X)
- Gil Harari (ORCID: https://orcid.org/0000-0002-4439-3219)
- Ariel Kerpel (ORCID: https://orcid.org/0000-0002-6430-0948)
- Yael Nissan
- Sigal Tal
- David Magalashvili (ORCID: https://orcid.org/0000-0003-0133-5040)
- Anat Achiron (ORCID: https://orcid.org/0000-0002-2020-3126)
Institutions
- Tel Aviv University (IL)
- Sheba Medical Center (IL)
- Assaf Harofeh Medical Center (IL)
- University of Haifa (IL)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1177/13524585251313749
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.41